1322P - Stereotactic radiosurgery (SRS) for spinal tumors: The Philippine experience

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Palliative Care
Surgical Oncology
Therapy
Radiation Oncology
Presenter J Richelcyn Baclay
Citation Annals of Oncology (2016) 27 (6): 455-461. 10.1093/annonc/mdw384
Authors J.R.M. Baclay1, A.D. Gaerlan2, I.M. Sih3, K.J. Cortez1, J.C. Rojales1, M.J. Calaguas1, J.M. Magsanoc1, R.A.D. Torcuator3
  • 1Radiation Oncology, St. Luke's Medical Center, 1112 - Taguig City/PH
  • 2Radiation Oncology, St. Luke's Medical Center, Taguig City/PH
  • 3Neurosurgery, St. Luke's Medical Center, Taguig City/PH

Abstract

Background

Although stereotactic radiosurgery (SRS) for spinal tumors has shown promising results, it has been used sparingly. This study aims to establish the temporal profile, as well as the number of patients who had pain relief, to characterize any toxicity experienced, and to determine the clinical outcomes of patients who underwent spine SRS.

Methods

From Aug 2012- Dec 2015, 20 patients who underwent spine SRS in this institution were retrospectively reviewed. Pain outcome was measured using the Numerical Rating Pain Scale. Neurologic examination was done by the attending neurosurgeon and the radiation oncologist. Acute effects were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) v4. The mean age of patients was 58 ± 16.06 years. Radiation was delivered via intensity modulated radiation therapy (IMRT) and prescribed to cover at least 80% of the planning treatment volume (PTV), with organs-at-risk doses kept to tolerance level. Patients were treated to a median dose of 16Gy (range 12-25Gy), given in 1-5 fractions.

Results

Spine SRS was performed in a total of 30 spinal tumors from 24 patients (7 primary spinal tumors, 23 metastatic). The most common origins of the metastatic lesions were prostate (4/23), renal cell (2/23), lung (2/23), and breast (2/23) cancers. The most common treated primary spinal tumor was schwannoma (4/7). A total of 4, 20, 1, and 5 lesions were treated in the cervical, thoracic, lumbosacral, and lumbar spine, respectively. None of the patients received previous irradiation to the spine. Pain was present in 18 of the patients pre-SRS. Thirty-eight presented with complete pain relief one day after the treatment, and increased to 83%, one month after SRS. The treatment was well tolerated with none of the patients experiencing toxicities such as nausea, vomiting, and headache. Only one patient experienced pain flare two days after the treatment, which resolved with steroids. One patient developed vertebral compression fracture two months after treatment, and was managed subsequently. Of the 10 patients who had motor deficits pre-SRS, 3 had complete recovery of motor function, while 7 had partial improvement.

Conclusions

SRS for spinal tumors is well-tolerated, safe, and effective treatment option.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.